Summary

Review of : Phase III PALLAS Trial Final protocol-planned analysis results, CCTG MA.32 a Phase III Randomized trial , and the RxPONDER updated results from the Phase III

Highlights

  • 1

    Phase III PALLAS Trial Final protocol-planned analysis results, the addition of palbociclib to adjuvant ET did not prolong iDFS compared to ET alone in patients with stage II-III HR+/HER2- breast cancer.

  • 2

    The CCTG MA.32 a Phase III Randomized trial does not improve IDFS, OS or other BC outcomes in moderate/high risk ER/PgR+ or ER/PgR - breast cancer patients and should not be used as breat cancer treatment in those groups.

  • 3

    RxPONDER updated results from the Phase III in patients with 1-3 positive lymph nodes, HR+ / HER2- Breast cancer with recurrence score of 25 or less reports that postmenopausal women with RS0-25 continue to not benefit from adjuvant chemotherapy.

  • 4

    Premenaupausal women with RS 0-25 benefit from the addition of chemotherapy to endocrine therapy, with a 44-46% decrease in IDFS,DRFS, DRFI events.

Comments (1)

  •
    Gilles Sigouin

    Test